<DOC>
	<DOC>NCT00291798</DOC>
	<brief_summary>The objective of the present clinical investigation is to determine whether hormonal therapy given preoperatively is able to reduce tumor size to an extent that facilitates breast-conserving procedures.</brief_summary>
	<brief_title>Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane</brief_title>
	<detailed_description>This open, prospective multicenter Phase II pilot trial investigates the efficacy of exemestane, 25 mg once daily over 4 months, in postmenopausal women with primary breast cancer, measured in terms of clinical response</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Histologically verified breast cancer (punch biopsy), established HER2/neu status Postmenopausal patients (&gt; 1 year following outset of menopause and/or postmenopausal hormonal profile) Clinical staging: T2 (&gt; 3 cm), T3, T4ac, N01 Hormone receptor positivity, i.e. estrogen and/or progesterone receptor &gt; 10 fmol/mg cytosolic protein or ERICApositive and/or PgRICApositive. Positivity of + (lowgrade) in one hormone receptor is only eligible in the presence of positivity in the other hormone receptor. no internal contraindication life expectation &gt; 6 month written informed consent premenopausal patients and patients with no clearly indicated menopausal status manifest second malignant tumor (except basalioma or in situ carcinoma of cervix uteri) uncontrolled internal disease i.e. diabetes mellitus, cardiac disease (NYHA III/IV) thromboembolic disease inflammatory mamma carcinoma existence of distant metastases former or simultaneously therapy with antioestrogens, aromatase inhibitors, cytostatics or radiotherapy corticosteroids before and during the study (except inhalant application) lack of compliance</criteria>
	<gender>Female</gender>
	<minimum_age>59 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>pilot study</keyword>
	<keyword>exemestane</keyword>
	<keyword>endocrinotherapy</keyword>
	<keyword>mamma carcinoma</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>ABCSG</keyword>
	<keyword>17</keyword>
</DOC>